BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius

Reuters

04-29

BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius

April 29 (Reuters) - SANDOZ GROUP AG SDZ.S:

SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS
SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS
AGREEMENT VALUED AT UP TO USD 301 MILLION
CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU
TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB
AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION

Source text: ID:nGNE8k7F37

Further company coverage: SDZ.S

(Gdansk Newsroom)

((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2531754916"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531754916\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531754916?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531754916","market":"nz","top_or_hot":-1,"title":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>SANDOZ GROUP AG <span>SDZ.S</span>:</p><ul><li><p>SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS</p></li><li><p>SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS</p></li><li><p>AGREEMENT VALUED AT UP TO USD 301 MILLION</p></li><li><p>CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU</p></li><li><p>TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB</p></li><li><p>AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION</p></li></ul><p>Source text: <span>ID:nGNE8k7F37</span></p><p>Further company coverage: <span>SDZ.S</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-29 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>SANDOZ GROUP AG <span>SDZ.S</span>:</p><ul><li><p>SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS</p></li><li><p>SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS</p></li><li><p>AGREEMENT VALUED AT UP TO USD 301 MILLION</p></li><li><p>CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU</p></li><li><p>TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB</p></li><li><p>AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION</p></li></ul><p>Source text: <span>ID:nGNE8k7F37</span></p><p>Further company coverage: <span>SDZ.S</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA3DHRXJ:1","article_id":"2531754916","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531754916","pubTimestamp":1745938928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With HenliusApril 29 (Reuters) - SANDOZ GROUP AG SDZ.S:SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADIN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-山德士集团与复宏汉霖签署全球合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9},"content_text":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With HenliusApril 29 (Reuters) - SANDOZ GROUP AG SDZ.S:SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONSSIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUSAGREEMENT VALUED AT UP TO USD 301 MILLIONCORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EUTO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMABAGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLIONSource text: ID:nGNE8k7F37Further company coverage: SDZ.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}